A Phase 2/3 interventional study of Cardiac Resynchronization Therapy Device in Cardiomyopathy, sponsored by Yuksek Ihtisas Hospital. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-09-25.
Sponsored by Yuksek Ihtisas Hospital · Phase 2/3 and Interventional
The purpose of this study is to determine clinical outcomes related to deactivation of Cardiac Resynchronization Therapy device in subjects with super response.
1,176 studies on the registry are indexed under Cardiomyopathies; 287 are open to participants now.
This study's enrollment of 19 is below the median of 51 across 609 interventional studies indexed under Cardiomyopathies.
Browse Cardiomyopathies studies →Yuksek Ihtisas Hospital is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Deactivated device group
Device: Cardiac Resynchronization Therapy Device
Ongoing device activity group
Cardiac Resynchronization Therapy Device pacing activity, on or off
Clinical/Echocardiographic outcome
Clinical/Echocardiographic outcome including New York Heart Association class, 6-min walk test, Left ventricular ejection fraction, Left ventricular end- diastolic diameter, Left ventricular end-systolic volume, and Left ventricular end-systolic diameter.
Time frame: 12 months
Mortality
Number of participants experiencing mortality
Time frame: 12 months
Heart failure hospitalization
Number of participants experiencing heart failure hospitalization
Time frame: 12 months
Cardiac Resynchronization Therapy Device intervention
Heart failure hospitalization Cardiac Resynchronization Therapy Device intervention for detected episodes.
Time frame: 12 months
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yuksek Ihtisas Hospital